- Home
- SCNX vs LTRN Comparison
SCNX vs LTRN Comparison
Compare SCNX & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCNX | LTRN |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2M | 27.6M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SCNX | LTRN |
|---|---|---|
| Price | $0.27 | $1.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.50 |
| AVG Volume (30 Days) | ★ 612.4K | 236.0K |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.65 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,831,778.00 | N/A |
| Revenue This Year | $1,009.57 | N/A |
| Revenue Next Year | $259.51 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 30.72 | N/A |
| 52 Week Low | $0.24 | $1.01 |
| 52 Week High | $2.60 | $4.70 |
Technical Indicators
Market Signals| Indicator | SCNX | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 20.94 | 19.79 |
| Support Level | $0.24 | N/A |
| Resistance Level | $0.43 | $1.96 |
| Average True Range (ATR) | 0.02 | 0.17 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 4.64 | 7.35 |
Price Performance
Historical ComparisonAbout SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.